Zinc deficiency alters responsiveness to antidepressant drugs in mice. (Q48436906)

11 February 2018

title

Zinc deficiency alters responsiveness to antidepressant drugs in mice. (English)

1 reference

11 February 2018

author

Bogusława Budziszewska

Bogusława Budziszewska

2

0 references

Gabriel Nowak

Gabriel Nowak

6

0 references

Urszula Doboszewska

Urszula Doboszewska

4

0 references

Andrzej Pilc

5

Andrzej Pilc

1 reference

11 February 2018

1

Katarzyna Młyniec

1 reference

11 February 2018

Witold Reczyński

3

Witold Reczyński

1 reference

11 February 2018

publication date

1 January 2013

1 reference

11 February 2018

published in

Pharmacological Reports

1 reference

11 February 2018

volume

65

1 reference

11 February 2018

issue

3

1 reference

11 February 2018

page(s)

579-592

1 reference

11 February 2018

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc and human health: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Chronic unpredictable stress-induced reduction in the hippocampal brain-derived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Intravenous ketamine for treatment-resistant major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Interaction of zinc with antidepressants in the tail suspension test

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Nitric oxide and major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Signaling pathways underlying the rapid antidepressant actions of ketamine

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Diagnosis and definition of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Definition and epidemiology of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Emerging role of glutamate in the pathophysiology of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

The role of glutamate on the action of antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Antidepressant-like properties of zinc in rodent forced swim test

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc: the new antidepressant?

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Lower serum zinc in major depression in relation to changes in serum acute phase proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Hypozincemia in depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Ketamine for treatment-resistant unipolar depression: current evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc in depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc deficiency induces behavioral alterations in the tail suspension test in mice. Effect of antidepressants.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Stress, glucocorticoids and glutamate release: effects of antidepressant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Serum trace elements in animal models and human depression. Part I. Zinc

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

High-affinity zinc inhibition of NMDA NR1-NR2A receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Research issues in the study of difficult-to-treat depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Serum zinc level in depressed patients during zinc supplementation of imipramine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Antidepressants for the new millennium

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Glutamate-based antidepressants: 20 years on.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Treatment resistant depression: methodological overview and operational criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Antidepressant-like activity of zinc: further behavioral and molecular evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Investigational NMDA receptor modulators for depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc signaling through glucocorticoid and glutamate signaling in stressful circumstances

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Attenuation of abnormal glutamate release in zinc deficiency by zinc and Yokukansan

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Anxiety-like behavior of young rats after 2-week zinc deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc homeostasis in the hippocampus of zinc-deficient young adult rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Hippocampal calcium dyshomeostasis and long-term potentiation in 2-week zinc deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Behavior in the forced swim test and neurochemical changes in the hippocampus in young rats after 2-week zinc deprivation.

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc deficiency induces depression-like symptoms in adult rats

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Antidepressants: past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Susceptibility to stress in young rats after 2-week zinc deprivation

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

An open-label trial of riluzole in patients with treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1016%2FS1734-1140%2813%2971035-1

7 January 2021

10.1016/S1734-1140(13)71035-1

Identifiers

DOI

1 reference

11 February 2018

PubMed ID

23950580

1 reference

11 February 2018